Marker Therapeutics, Inc. (MRKR) Income Statement
MRKR 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsMRKR revenue and net income
Where MRKR's revenue goes
2025Each bar shows an amount and its share of revenue. MRKR kept −343.0% of revenue as net income.
MRKR profit margins
MRKR growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −46.2% | +0.3% | +50.0% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
MRKR quarterly EPS vs estimates
Marker Therapeutics beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 12, 2026 (estimate $-0.12).
MRKR income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5M | $6.6M | $3.3M | $3.5M | $1.2M | $466,785 | $213,194 | $205,994 | $183,064 | $0 |
| Cost of revenue | — | $13.5M | $10.4M | $12.0M | $3.2M | $18.9M | $12.8M | $124.0M | $5.3M | $0 |
| Gross profit | — | −$6.9M | −$7.1M | −$8.5M | −$1.9M | −$18.4M | −$12.6M | −$123.8M | −$5.1M | $0 |
| Research & development | $11.8M | $13.5M | $10.4M | $12.0M | $27.8M | $18.9M | $12.8M | $124.0M | $5.3M | $3.8M |
| Sales, general & admin | $4.2M | $4.2M | $7.5M | $11.3M | $12.9M | $10.5M | $10.0M | $24.4M | $6.4M | $4.7M |
| Total operating expenses | $12.9M | $4.2M | $7.5M | $11.3M | $37.6M | $10.5M | $10.0M | $148.4M | $6.4M | $8.3M |
| Operating income | −$12.9M | −$11.1M | −$14.6M | −$19.8M | −$39.5M | −$28.9M | −$22.5M | −$148.2M | −$11.5M | −$8.5M |
| Interest income | $594,206 | $437,010 | $447,229 | $248,063 | $5,700 | $148,742 | $1.1M | $253,723 | — | — |
| Interest expense | — | — | — | $15,089 | $5,700 | $148,742 | $0 | $0 | $0 | $0 |
| Income before taxes | −$12.2M | −$10.7M | −$14.0M | −$19.8M | −$41.9M | −$28.7M | −$21.4M | −$148.0M | −$11.0M | −$2.5M |
| Income taxes | −$15,156 | $49,953 | $3,675 | −$15,089 | −$5,700 | −$180,000 | −$1.1M | −$214,000 | −$681,000 | −$6.0M |
| Net income | −$12.2M | −$10.7M | −$8.2M | −$29.9M | −$41.9M | −$28.7M | −$21.4M | −$148.0M | −$11.0M | −$2.5M |
| EBITDA | −$12.4M | −$10.7M | −$11.3M | −$16.1M | −$38.7M | −$27.6M | −$22.2M | $205,633 | $183,042 | $6.0M |
| EPS (diluted) | −$0.85 | −$1.20 | −$1.10 | −$6.37 | −$5.50 | −$6.20 | −$4.70 | −$14.11 | −$3.90 | −$0.93 |
| Gross margin | — | −104.3% | −214.6% | −240.6% | −154.7% | −3,944.9% | −5,887.4% | −60,095.0% | −2,768.4% | — |
| Operating margin | −363.5% | −168.7% | −440.4% | −563.3% | −3,179.3% | −6,188.3% | −10,567.3% | −71,930.3% | −6,271.0% | — |
| Net margin | −343.0% | −162.8% | −248.8% | −851.9% | −3,372.7% | −6,149.7% | −10,050.9% | −71,826.4% | −5,999.0% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.1M | $1.2M | $861,184 | $349,104 | $2.3M | $1.9M | $1.2M | $1.2M | $1.1M | $257,606 |
| Cost of revenue | — | $2.8M | — | $2.3M | $4.2M | $3.1M | $5.1M | $3.5M | $2.3M | $2.6M | $2.6M | $2.0M |
| Gross profit | — | −$2.8M | — | −$1.1M | −$3.3M | −$2.8M | −$2.8M | −$1.5M | −$1.2M | −$1.3M | −$1.6M | −$1.8M |
| Research & development | $1.5M | $2.8M | $2.1M | $2.3M | $4.2M | $3.1M | $5.1M | $3.5M | $2.3M | $2.6M | $2.6M | $2.0M |
| Sales, general & admin | $1.1M | $1.2M | $846,606 | $1.0M | $945,163 | $1.4M | $1.0M | $854,677 | $1.1M | $1.2M | $1.4M | $1.4M |
| Total operating expenses | $2.6M | $1.2M | $1.9M | $1.0M | $945,163 | $1.8M | $1.0M | $854,677 | $1.1M | $1.2M | $1.4M | $1.4M |
| Operating income | −$2.6M | −$4.1M | −$1.9M | −$2.1M | −$4.3M | −$4.6M | −$3.9M | −$2.4M | −$2.3M | −$2.5M | −$2.9M | −$3.2M |
| Interest income | $112,558 | $132,889 | $165,628 | $138,064 | $128,025 | $162,489 | $73,746 | $91,681 | $115,388 | $156,195 | $201,339 | $218,085 |
| Interest expense | — | — | — | — | — | — | $437,010 | — | — | — | $84,000 | — |
| Income before taxes | −$1.8M | −$3.2M | −$1.7M | −$2.0M | −$4.0M | −$4.4M | −$3.8M | −$2.3M | −$2.2M | −$2.4M | −$2.7M | −$3.0M |
| Income taxes | — | — | −$15,156 | — | — | — | $49,953 | — | — | −$2.5M | $3,675 | −$697,000 |
| Net income | −$1.8M | −$3.2M | −$1.7M | −$2.0M | −$4.0M | −$4.4M | −$3.8M | −$2.3M | −$2.2M | −$2.4M | −$2.8M | −$3.0M |
| EBITDA | −$1.8M | −$3.2M | −$1.7M | −$2.0M | −$3.2M | $349,104 | −$3.8M | −$2.3M | $115,388 | $156,195 | −$2.0M | −$2.3M |
| EPS (diluted) | −$0.09 | −$0.16 | −$0.04 | −$0.12 | −$0.29 | −$0.40 | −$0.42 | −$0.26 | −$0.25 | −$0.27 | −$0.48 | −$0.34 |
| Gross margin | — | — | — | −90.3% | −385.0% | −798.1% | −125.9% | −80.2% | −99.7% | −107.0% | −147.7% | −693.8% |
| Operating margin | — | — | −170.7% | −173.3% | −494.8% | −1,320.1% | −171.5% | −124.6% | −197.4% | −204.9% | −278.1% | −1,242.2% |
| Net margin | — | — | −154.4% | −162.1% | −466.3% | −1,273.6% | −170.4% | −119.8% | −187.5% | −192.3% | −265.3% | −1,157.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in MRKR's financial statements (latest annual report filed March 18, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
MRKR financial results
In fiscal year 2025 (ended December 31, 2025), Marker Therapeutics reported revenue of $3.5 million, down 46.2% from the year before. It had a net loss of $12.2 million, a net profit margin of −343.0%. Diluted earnings per share came to −$0.85. Over five years revenue grew at an average rate of 50.0% a year.
See the MRKR stock overview for the latest quote and news, or the MRKR chart for price history and technical indicators.
MRKR income statement FAQ
What is Marker Therapeutics's annual revenue?
Marker Therapeutics reported total revenue of $3.5 million for fiscal year 2025, which ended on December 31, 2025. That was down 46.2% from $6.6 million the previous year.
Is Marker Therapeutics profitable?
No. Marker Therapeutics reported a net loss of $12.2 million in fiscal 2025, a net profit margin of −343.0%; its operating margin was −363.5%.
How much does Marker Therapeutics spend on research and development?
Marker Therapeutics spent $11.8 million on research and development in fiscal 2025, 332.7% of revenue.
How fast is Marker Therapeutics growing?
Revenue grew 50.0% a year on average over the last five fiscal years, from $0.5 million to $3.5 million.
What are Marker Therapeutics's earnings per share?
Marker Therapeutics earned $-0.85 per diluted share in fiscal 2025, compared with $-1.20 a year earlier.
When will Marker Therapeutics report its next earnings?
Marker Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Marker Therapeutics's fiscal year end?
Marker Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 18, 2026.